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PENYARINGAN MAYA PROTEIN TIROSIN FOSFATASE 1B DALAM 
PENCARIAN HASILAN SEMULA JADI YANG MEMPUNYAI AKTIVITI 
BERPOTENSI TERHADAP DIABETES MELITUS JENIS 2 
 
 
ABSTRAK 
 
Populasi pesakit Diabetes Melitus Jenis 2 telah mencecah 422 juta orang daripada 
keseluruhan populasi dunia pada tahun 2014 dan dijangka akan mencapai kedudukan ketujuh 
sebagai penyebab utama kematian di tahun 2030 menurut Organisasi Kesihatan Dunia 
(WHO). Kajian telah menunjukkan 90-95% daripada penyakit diabetes terdiri daripada 
Diabetes Melitus Jenis 2 (T2DM). Berdasarkan peratusan tersebut, Diabetes Melitus telah 
merangkumi 6% daripada populasi orang dewasa di dalam kalangan masyarakat barat. Di 
Malaysia, penularan penyakit T2DM telah meningkat dua kali ganda dari 8.3% (1996) 
kepada 17.5% (2015) dalam tempoh sepuluh tahun. Kini, 1 daripada 5 rakyat Malaysia 
merupakan pengidap diabetik di mana 45% (1 juta orang) daripada populasi obesiti terdiri 
daripada kanak-kanak. Kajian ini melibatkan penyaringan maya ke atas sebatian dari 
pangkalan data Natural Product Discovert (NADI) terhadap protein tirosin fosfatase 1B 
(PTP1B) dengan menggunakan dua kaedah in silico untuk mengenalpasti sifat anti-diabetik 
daripada sebatian tersebut. PTP1B adalah penyelia negatif laluan isyarat insulin dan leptin. 
Bukti kajian menunjukkan bahawa perencat PTB1B mungkin sasaran dadah yang 
menyakinkan untuk pesakit T2DM dan obes-berisiko. Sebanyak 4000 sebatian telah melalui 
penyaringan maya dengan AutoDock 4.2 dan 1933 ligan telah diterjemahkan ke dalam 
model pharmacophore HYPO1menggunakan Discovery Studio 2.5. Sebanyak 18 tumbuhan 
telah dipilih selepas ikatan tenaga terendah (FEB), nilai kesesuaian (Fit Value), pembentukan 
ligan-protein, interaksi ligan-protein, populasi sebatian yang berkaitan, dan ketersediaan 
komersial ligan paling aktif daripada pemeriksaan kedua-dua penyaringan maya tersebut. 20 
ekstrak daripada tumbuhan yang di pilih kemudiannya dikenakan ujian in vitro enzimatik. 
Pandanus amaryllifolius (daun) menunjukkan peratusan perencat yang tertinggi, iaitu 
sebanyak 94.38%, dan diikuti oleh Vitex negundo (daun) (89.03%), Piper nigrum (buah) 
xii 
 
(81.39%), Cymbopogon nardus (daun) (79.78%), Artocarpus champeden (kulit) (66.90%), 
Cymbopogon nardus (daun) (66.02%) dan Manilkara zapota (buah) (62.06%). Kajian pada 
masa hadapan boleh ditumpukan untuk mengenalpasti unsur sebatian secara terperinci, 
“scaffold-hopping” terhadap ligan yang aktif, dan modifikasi kimia ke atas struktur sebatian 
perencat; untuk menemui perencat PTP1B yang lebih berkesan dan khusus untuk pesakit 
T2DM. 
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VIRTUAL SCREENING OF PROTEIN TYROSINE PHOSPHATASE 1B IN 
SEARCH FOR NATURAL PRODUCTS WITH POTENTIAL ACTIVITY  
AGAINST DIABETES MELLITUS TYPE 2 
 
 
ABSTRACT 
 
The world population of diabetes mellitus patients had reached 422 million in the 
year 2014 and projected to be the seventh leading cause of death in the year 2030 by World 
Health Organization. Type 2 Diabetes Mellitus (T2DM) was responsible for 90-95% of all 
diabetes and it had affected approximate 6% of the adult population in the western society. 
In Malaysia, the prevalence of T2DM had doubled from 8.3% (1996) to 17.5% (2015) in 
duration of ten years. Now, 1 out of 5 Malaysian are diabetic and with over 45% of 
overweight and obese population with 1 million obese children. This study involved virtual 
screening of the Natural Product Discovery (NADI) database compounds against protein 
tyrosine phosphatase 1B (PTP1B) using two in silico methods, molecular docking (structure-
based virtual screening) and pharmacophore mapping (ligand-based virtual screening), in 
order to predict their anti-diabetic properties. PTP1B is a negative regulator of both insulin 
and leptin signalling pathways. Evidence had shown that PTP1B inhibitors might be a 
convincing drug target for T2DM patients and at-risk obese patients. 4000 compounds from 
NADI database were virtually screened using AutoDock 4.2 while 1933 ligands were 
mapped to pharmacophore model HYPO1 using Discovery Studio 2.5. 18 plants were 
selected after cross examine the lowest binding energy (FEB), fit value, ligand-protein 
conformation, ligand-protein interactions, the population of the related compound and 
commercial availability in the virtually active top hits from two virtual screening results. 20 
extracts from 18 selected plants were then subjected to in vitro enzymatic assay. Pandanus 
amaryllifolius (leaves) showed highest inhibitory at 94.38% followed by Vitex negundo 
(leaves) (89.03%), Piper nigrum (fruits) (81.39%), Cymbopogon nardus (leaves) (79.78%), 
Cymbopogon nardus (peel) (66.90%), Cymbopogon nardus (leaves) (66.02%) and 
Manilkara zapota (fruits) (62.06%). Future studies focusing on compounds elucidation, 
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scaffold-hopping of virtually active ligands, and chemical modification of the structure of 
inhibiting compounds could be carried out in order to discover a more potent and specific 
PTP1B inhibitor for drug design in the prospect of T2DM. 
 
  
CHAPTER ONE 
INTRODUCTION 
 
1.1 Statement of Problem 
Diabetes mellitus is one of the most common chronic, non-communicable, diseases around 
the world (Whiting et al., 2011). The ever-changing lifestyle with reduced physical activity 
and increased obesity along the economic development and urbanization had significantly 
increased the prevalence of diabetes mellitus patients globally. The number of people with 
diabetes had risen tremendously from 108 million in the year 1980 to 422 million in the year 
2014 (WHO, 2016). It is the major cause of blindness, kidney failure, heart attacks, stroke 
and lower limb amputation, and The World Health Organization (WHO) is projecting 
diabetes to be the seventh leading cause of death in the year 2030 (WHO, 2016). The studies 
all over the world showed that the prevalence of Type 2 Diabetes Mellitus (T2DM) is 
escalating at phenomenal scale and most likely heading towards epidemical level (Zaini, 
2000). 
 
 Diabetes prevalence has been rising more rapidly in middle and low-income 
countries (WHO, 2016) and the projected rise (from the year 1995 to the year 2025) in 
developed countries is 42% whereas developing countries will witness an escalation of 170% 
(King et al., 1998). In Malaysia, the prevalence of diabetes mellitus (18 years old and above) 
had risen from 8.3% in the year 1996 to 17.5% in the year 2015 (Malaysia Institute For 
Public Health, 2015). It is estimated that 3.5 million Malaysian are diabetic or, in another 
word, 1 out of 5 Malaysian is living with this chronic disease. The situation in Malaysia 
became more agonised as the overweight (BMI between 25 kg m-2 and 30 kg m-2) and obese 
(BMI above 30 kg m-2) population had risen from 16.6% and 4.4%, respectively, in the year 
1996 to 30% and 17.7%, respectively, in the year 2015. At the same time, Malaysia has 1 
million obese children (below 18 years old) which represent 11.9% of the total underage 
population (Malaysia Institute For Public Health, 2015).  
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 Although varies diabetes treatments are available in the market but most of these 
treatments are not only costly but also causing side effects, such as nausea, migraine and 
fatigue. Weight gain is one of the most common side effects from T2DM treatments due to 
the close relationship between insulin and lipase pathway. Obesity is the state of increased 
body weight (especially adipose tissues) of a certain level to cause advert health issue 
(Spiegelman & Flier, 2001). This is a vicious circle for T2DM patients as weight gain is a 
commonly recognised contributing factor for insulin resistance, impaired glucose tolerance 
(IGT) and T2DM. New therapies through different pathways and provoke less side effects 
are necessary.  
 
 In the recent decades, protein tyrosine phosphatase 1B (PTP1B) had emerged as a 
new potential target in the road of finding a cure for T2DM. T2DM is strongly associated 
with obesity and insulin resistance act as a common link between them. The inhibition of 
PTP1B might enhance the action of insulin and give advantage in T2DM treatment (Zhang 
& Lee, 2003). With all the evidence published throughout the decades, PTP1B seems to be a 
convincing candidate at all genetic, molecular, biochemical and physiological level for drug 
design in order to treat T2DM and at-risk obese patients (Johnson et al., 2002). 
 
1.2 Objectives and Scopes of Study 
This study involved screening of the Malaysian Plants’ Natural Products from Natural 
Products Discovery (NADI) database using two different in silico methods in order to predict 
their antidiabetic properties. First, virtual screening was conducted using both structure –
based molecular docking and ligand-based pharmacophore mapping. The compounds in the 
database were subjected to PTP1B, an enzyme that played important role in negative 
regulation of insulin pathway, associating with metabolic syndrome and type 2 diabetes 
mellitus. A few host plants for the top ranked compounds from the virtual screening were 
then preceded to bio-assay guided extraction. These extracts were evaluated using enzymatic 
bio-assay.  
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The final validated antidiabetic properties were then cross referenced with literature 
and ethno-medical knowledge in the aim to find a competitive PTP1B inhibitor which acted 
as a starting point for optimisation in the drug design. 
 
Specifically, the objectives of this study are: 
1. To screen for Protein Tyrosine Phosphatase 1B (PTP1B) inhibitors using Natural 
Products Discovery (NADI) database implicated in diabetes mellitus type 2. 
2. To validate in silico predictions using suitable in vitro assay. 
3. To correlate these predictions and confirmation of the antidiabetic properties with 
ethno-medical uses.  
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.1 Diabetes Mellitus 
Diabetes is a heterogeneous group of disorders occurred either when the pancreas do not 
produce enough insulin or the body cannot effectively use the insulin it produces (WHO, 
2016). This disease is now a major public health problem listed on the four priority non-
communicable diseases (NCDs) along side with cardiovascular diseases, cancer and chronic 
lung diseases. Historically, the word diabetes which means “to pass through” in Greek was 
first used by Apollonius of Memphis in 230 BC. The modern classification of diabetes 
mellitus and the tests used for its diagnosis were created by the National Diabetes Data 
Group of the USA and the second World Health Organization (WHO) Expert Committee on 
Diabetes Mellitus in the year 1979 and 1980 (Alberti & Zimmet, 1998).  
 
Diabetes is categorised into four clinical classifications: Type 1 diabetes mellitus 
(T1DM) (previously known as insulin-dependent diabetes), Type 2 diabetes mellitus 
(T2DM) (previously known as non-insulin-dependent diabetes), gestational diabetes and 
diabetes due to other causes such as, genetic defects or medication by the American Diabetes 
Association (ADA) (Clark et al., 2012). Other than the four clinical classifications, WHO 
had also recognised impaired glucose tolerance (IGT) and impaired fasting glycaemia (IFG) 
as the intermediate conditions before diabetes. As the conditions are not inevitable, those 
with these transition conditions are taken in to account for undiagnosed or potential diabetes 
patient (especially T2DM). The diagnosis criteria for diabetes were illustrated in Table 2.1.  
 
Table 2.1 Diagnosis criteria for diabetes using oral glucose tolerance test. 
Fasting plasma glucose, mmol/L 
< 6.1 Normal 
6.1 – 6.9 Impaired fasting glycaemia (IFG) 
≥ 7.0 Diabetes 
2-hours plasma glucose, mmol/L 
< 7.8 Normal 
7.8 – 11.0 Impaired glucose tolerance (IGT) 
≥ 11.0 Diabetes 
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T1DM is mainly caused by insulin deficiency in the body. Patients with T1DM 
needed daily insulin injection to help regulate the blood glucose level. Unfortunately, T1DM 
cannot be prevented with the current understanding and knowledge. The cause remained 
unknown. T1DM patients will not survive without regular insulin administration. On the 
other hand, T2DM are the result of insulin inefficacy, in term of both, action and excretion 
(Nolan, 2002). It is a chronic and progressive metabolic disorder characterised by 
hyperglycaemia.  
 
The blood glucose level is regulated by insulin and glucagon hormones. Insulin is 
primarily excreted from β-cell of the Islet of Langerhans in pancreas while glucagon is 
expressed from the α-cell of the pancreas. Insulin inhibits glycogenolysis, gluconeogenesis, 
lipolysis, proteolysis and ketogenesis but at the same time promote glucose uptake in muscle 
and adipose tissues. On the other hand, glucagon acts as an antagonist of insulin in the liver 
increasing the blood glucose level (Clark et al., 2012).  
 
A diabetic individual may express symptoms such as excessive urination (polyuria) 
and great thirst (polydipsia), constant hunger, weight loss, vision changes and fatigue. These 
symptoms are remarkably more severe in T1DM patients while sometimes recorded as 
absent by T2DM patients.  
 
2.1.1 Type 2 Diabetes Mellitus in the world  
As reported by WHO (WHO, 2016), there are estimated 422 million diabetic adults in the 
year 2014. More than 6% of the adult population from the Western society is afflicted by 
diabetes and T2DM responsible for 90-95% of the total prevalence (Moller, 2001). The 
global prevalence of diabetes nearly doubled from 4.7% of 1980 to 8.5% of 2014. 
International Diabetes Foundation (IDF) projected that the global diabetes prevalence will 
reach 552 million by 2030 (Whiting et al., 2011) while WHO projected it as the seventh 
leading cause of death in the same year. The diabetes prevalence in middle and low-income 
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countries are rising more rapidly compared to high-income countries. IDF predicted the 
African region to have the largest proportional increase in diabetic adult number by 2030 
followed by the Middle East and North Africa region. However, the Western Pacific region 
will continue to have the largest number of diabetic adults primarily due to the large diabetic 
population in China.  
 
 In 2012, an estimated of 1.5 million deaths worldwide are directly due to diabetes. It 
is the eighth leading cause of death among all gender and fifth leading cause of death among 
women (WHO, 2016). The numbers increases to 1.6 million in the year 2015 (WHO, 2017). 
Diabetes mellitus is also well known for its development of complications if the patient 
didn’t manage the blood glucose level well. Diabetic ketoacidosis (DKA) (T1DM and 
T2DM) and hyperosmolar coma are common complications triggered by constant high blood 
glucose level. Prolonged diabetes will damage the heart, blood vessels, eyes (retinopathy), 
kidneys (one of the leading cause of kidney failure), nerves and increase the risk of stroke. 
Serious neuropathy in limbs might lead to amputation. Statistically, atherosclerotic 
cardiovascular disease (ASCVD) had been reported account for 80% of diabetic mortality 
and more than 75% of all hospitalisations for diabetic complications (Moller, 2001). The 
total deaths related to high blood glucose level is approximately 3.7 million in the year 2012 
including 2.7 million deaths from diabetic related complications (Figure 2.1). Of these, 
Middle and low-income countries contributed the highest death proportion in all age group 
and significantly increased after age of 50 (Figure 2.1).  
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Figure 2.1 Percentage of all cause deaths attributed to high blood glucose, by age and 
country by income group in 2012 (categorised by the Wolrd Bank, 2012). Graph A for male 
and graph B for female, respectively (WHO, 2016). 
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2.1.2 Type 2 Diabetes Mellitus in Malaysia 
The MalaysiaNational Health and Morbidity Survey (NHMS) is a nationwide survey 
initiated in the year 1986 which aims to monitor the health and nutritional level of 
Malaysian. The interval of the NHMS had shortened into every 4 years instead of 10 since 
the year 2011. In the year 2015, diabetes mellitus prevalence in Malaysia had reached 17.5% 
(approximately 3.5 million) of the population (Table 2.2) (Institute For Public Health, 2015; 
Letchuman et al., 2010). The figure had doubled from 8.3% (1996) to 17.5% (2015) in the 
duration of ten years.  The situation in Malaysia has became more agonised as the 
overweight and obese Malaysian had risen from 16.6% and 4.4%, respectively, in the year 
1996 to 30% and 17.7%,respectively, in the year 2015 (Table 2.3) (Institute For Public 
Health, 2015; Letchuman et al., 2010). At the same time, Malaysia has 1 million obese 
children (below 18 years old) which represent 11.9% of the total underage population 
(Institute For Public Health, 2015). It is generally agreed that ethnicity, family history of 
diabetes, overweight and obesity, physical inactivity and smoking are risk factors for T2DM 
(WHO, 2016). With over 45% of total obesity and pre-obese population and 22.8% of the 
smoking community, T2DM had already risen as one of the major public health problems in 
Malaysia. Fortunately, with the increase of awareness, risk factor physical inactivity had 
decreased from 88.4% (1996) to 33.5% (2015) (Table 2.3) (Institute For Public Health, 2015; 
Letchuman et al., 2010). 
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Table 2.2 Prevalence of diabetes in Malaysia from Malaysia National Health 
Morbidity Surveys (Institute For Public Health, 2015; Letchuman et al., 2010). 
 
 
NHMS II 
(1996) 
NHMS III 
(2006) NHMS 2011 NHMS 2015 
Age group ≥30 years ≥18 years ≥18 years Est. Population ≥18 years 
Est. 
Population 
Prevalence 8.3% 11.6% 15.2% 2,622,284 17.5% 3,500,000 
Known 
diabetes 6.5% 7.0% 7.2% 1,247,366 8.3% N/A 
Undiagnosed 1.8% 4.5% 8.0% 1,374,918 17.2% N/A 
Impaired 
Glucose 
Tolerance * / 
Impaired 
Fasting 
Glucose ** 
4.3% * 4.2% ** 4.9% ** 841,477 N/A N/A 
 
 
 
Table 2.3 Prevalence of nutritional status and dietary practise of Malaysian from 
Malaysia National Health Morbidity Surveys (Institute For Public Health, 2015; Letchuman 
et al., 2010). 
 
 
NHMS II 
(1996) 
NHMS III 
(2006) 
NHMS 
2011 
NHMS 
2015 
Age group ≥18 years ≥18 years ≥18 years ≥18 years 
Smoking 24.8% 21.5% 23.1% 22.8% 
Fruits & Vegetable < 5 
servings/day N.A. N.A. 92.5% 94.0% 
Physically Inactive 88.4% 43.7% 35.2% 33.5% 
Overweight 
(BMI ≥25 kg/m2 & < 30 
kg/m2) 
16.6% 29.1% 29.4% 30.0% 
Obesity (BMI  ≥ 30 kg/m2) 4.4% 14.0% 15.1% 17.7% 
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2.1.3 Relationship between insulin signalling pathway and Type 2 Diabetes Mellitus 
Pathophysiology of a disease determined its treatment. There are three events occurred in a 
coordinated manner after the ingestion of glucose (DeFronzo, 1999). First, the secretion of 
insulin. Secondly, the suppression of endogenous (primarily hepatic) glucose production by 
insulin. Then, insulin will trigger the glucose uptake by peripheral tissue, mainly muscles. 
Insulin is the most potent known anabolic hormone which is in charge of the synthesis 
promotion and storage of carbohydrates, lipids and proteins while inhibiting their 
degradation and release in circulation (Figure 2.2) (Saltiel & Kahn, 2001). Pancreatic cells, 
the primary insulin secretion cell, are capable of moderate insulin action and secretion 
accordingly. IGT or IFG will develop whenever pancreatic β-cell could not function properly 
for a prolonged duration. 
 
Insulin resistance, a condition of insulin inefficacy, was first reported by Himsworth 
in 1936 based on his observation of decreased insulin action in obese patients (Himsworth, 
2013). It is the hallmark of T2DM which indicates attenuated insulin effect to promote 
glucose transport and metabolism in peripheral tissues, such as liver, adipose and skeletal 
muscle (Zhang & Lee, 2003). Insulin action started when it binds to the insulin receptor (IR) 
and the conformation change will trigger autophosphorylation of several downstream protein 
substrates namely insulin receptor substrate (IRS) 1 to 4 and a few adapter proteins including 
Gab1 and Shc (Figure 2.3). The production of IRSs and adapter proteins triggered some 
important kinases in a very specific order. Phosphatidylinositol 3-kinase (PI3K) activated 
PI3K-dependent kinase 1 (PDK1) then protein kinase Akt. Akt is essential for glucose 
transporter translocation (GLUT4) in transporting glucose into the cell and glycogen 
synthase kinase (GSK-3) in glycogen synthesis (Saltiel & Kahn, 2001; Zhang & Lee, 2003).  
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Figure 2.2 Insulin stimulates the glucose, amino acids and fatty acids uptake, stop their 
degradation and promote enzyme expression or activity that synthesis glycogen, lipid and 
protein (modified from Saltiel & Kahn, 2001). 
 
 
 
Figure 2.3 Signal transduction of in insulin action (modified from Saltiel & Kahn, 
2001). 
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Insulin resistance in both T2DM and obesity involved defection in multiple levels 
including decreases in receptor concentration and kinase activity, the concentration and 
phosphorylation of IRS-1 to 4, PI3K activity, GLUT4 and the activity of intracellular 
enzymes (Pessin & Saltiel, 2000). On the other hand, the defects in genetic or acquired 
factors, even though rare, can cause the most severe form of insulin resistance (Taylor 
Simeon & Arioglu, 1998). Table 2.4 and Table 2.5 summarised some important research 
observations involved in vivo targeted deletion of insulin signalling (homologous 
recombination) components and role of specific tissues in diabetes respectively (Saltiel & 
Kahn, 2001). Insulin sensitivity in PTP1B and SHIP2 knockout mice increased and GLUT4 
role in insulin resistance was once again being confirmed (Table 2.4 & Table 2.5).   
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Table 2.4 Mice phenotypes with single-gene knockouts in signalling pathways (Saltiel 
& Kahn, 2001). 
Gene Phenotype 
Insulin 
receptor 
Normal intrauterine growth; die of diabetec ketoacidosis at 3-7 days. 
IGF1 receptor Intrauterine and postnatal growth retardation; normal glucose homeostasis 
IRS1 Insulin resistance/ impaired glucose tolerane; IGF resistance/growth 
retardation  
IRS2 Insulin resistance/ decreased β-cell development; T2DM 
IRS3 Normal growth/ normal glucose tolerance 
IRS4 Normal growth/ normal glucose tolerance 
Akt Insulin resistance in liver and muscle 
GLUT4 Cardiac hypertrophy/ failure; normal glucose tolerance 
P85α Increased insulin sensitivity; hypoglycaemia 
PTP1B Increased insulin sensitivity; resistance to diet-induced obesity 
SHIP2 Increased insulin sensitivity 
 
 
Table 2.5 Defect s in tissues-specific knockout mice (Saltiel & Kahn, 2001).  
Gene Tissue Phenotype 
Insulin 
receptor 
Skeletal 
muscle 
Normal glucose tolerance; increased fat mass; increased 
triglycerides and FFAs 
Liver Impaired glucose tolerance; hyperinsulinaemia and 
reduced insulin clearance; decreased hepatic function 
β-cell Loss of glucose-stimulated insulin secretion; 
progressively impaired glucose tolerance; decreased β-
cell growth in adults 
Brain Increased appetite; increased fat and leptin; insulin 
resistance; hypothalamic hypogonadism 
GLUT4 Skeletal 
muscle 
Reduced basal, insulin and contraction-stimulation 
glucose transport; severe insulin resistance; glucose 
intolerance 
Fat Impaired glucose tolerance; hyperinsulinaemia; secondary 
insulin resistance in muscle and liver 
Glukokinase β-cell Die within a few days of birth with severe diabetes 
Liver  Mild hyperglycaemia; pronounced defects in glycogen 
synthesis and glucose turnover; impaired glucose-
stimulated inculin secretion 
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2.1.4 Therapeutic approaches in Type 2 Diabetes Mellitus 
In the old days, T2DM was believed could not be cured and hence the patients were advised 
to manage their blood glucose level by oral administration drugs or insulin injection 
(pharmacological agents), diet and lifestyle adjustment in order to delay the development of 
severe insulin resistance or complications for prolonged high blood glucose level (Moller, 
2001; Olokoba et al., 2012). Current therapeutic approaches are mainly developed with the 
absence of defined molecular target but targeting classic action sites such as liver and 
pancreas (Table 2.6) (Moller, 2001) with a four fundamental pharmacological approaches 
including promoting insulin secretion, enhancing insulin efficiency (action), reducing 
excessive hepatic glucose production and inhibiting glucose absorption from the gut 
(Doherty, 2005). Weight gain is one of the common side effects from the current agents 
which lead to a vicious cycle for T2DM patients as weight gain is a commonly recognised 
contributing factor for insulin resistance, IGT, IFG and T2DM.  
 
According to the United Kingdom Prospective Diabetes Study (UKPDS), T2DM can 
initially treat by mono-therapy but eventually required additional oral agent. In many cases, 
insulin therapy will be needed to achieve targeted blood glucose level (DeFronzo, 1999). 
Current treatments (Table 2.6) include injectable insulin and oral hypoglycemic agents such 
as metformin, sulfonylureas, the thiazolidinediones, and α-glucosidase inhibitors. However, 
no combination of these therapies is completely successful in ameliorating type II diabetes 
for many patients, and more efficacious agents are needed. A major goal of new therapies for 
T2DM is to potentiate the action of insulin (Szczepankiewicz et al., 2003).  
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Three striking characteristics of actions of drugs indicate very strongly that they are 
concentrated by cells in small, specific areas known as the receptor. The three characters are 
as following (Albert, 2013; Cushny, 1903): 
1. Drugs can retain its potency up to nanomolar level. 
2. Drugs having very high specificity, for example, D- and L- isomers of a substance 
can have different pharmacological actions. 
3. Drugs having very high biological specificity, for example, adrenaline works on 
cardiac muscle but its effect is very little on striatal muscle. 
 
Other than the pharmacological agents listed in Table 2.6, some new drugs were 
introduced in the recent years including incretin-based therapies (exenatide-imitative and 
Liraglutide), dipeptidyl peptidase-IV inhibitors, new insulin analogues (lispro, aspart, analog 
and glargine), inhaling insulin drug and bromocriptine (Olokoba et al., 2012). With the 
advance in biochemistry knowledge and increasing understanding in the diabetes 
pathophysiology, a few negative regulators of insulin signalling pathway, including PTP1B 
had been implicated as new novel drug targets (Table 2.7) (Moller, 2001).  
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Table 2.6 Current therapeutic agents for T2DM. 
Drug class Molecular target Site of action Adverse events 
Insulin Insulin receptor Liver, muscle, fat Hypoglycaemia; 
weight gain 
Sulphonylureas 
(glibenclamide, 
nateglinide, 
repaglinide)  
SU receptor/ K+ ATP channel Pancreas β-cell Hypoglycaemia 
Metformin-
biguanides Unknown Liver, muscle 
Gastrointestinal 
disturbances; lactic 
acidosis 
Acarbose α-glucosidase Intestine Gastrointestinal disturbances 
Pioglitazone, 
rosiglitazone 
(thiazolidinedio
nes)  
PPARγ Fat, muscle, liver Weight gain; oedema; 
anaemia 
 
 
Table 2.7 Potential drug targets in the insulin signalling pathway. 
Target Validation Potential mechanism 
Insulin 
receptor 
Insulin, small molecule 
activators/ potentiators 
Apparent direct activation of the 
receptor 
PTP1B Efficacy of vanadium 
compounds; PTP1B knockout 
mice (insulin sensitivity 
increased and resist to obesity); 
efficacy of PTP1B antisense 
oligonucleotide 
Mediates dephosphorylation of insulin 
receptor  
SHP2 SHP2 knockout mice (insulin 
sensitivity increased) 
Dephosphorylation of 
phosphionositides 
GSK3 Efficacy of GSK3 inhibitors in 
rodent models 
Phosphorylation of glycogen synthase 
eading to inhibition of glycogen 
synthesis; potential negative regulator 
of other insulin signalling events 
IkB kinase Efficacy of high-dose salicylate 
(inhibits IkB kinase); IkB kinase 
knockout mice (insulin sensitivity 
increased) 
Serine-threonine phosphorylation of 
insulin signalling intermediates 
PKCθ Activated in muscle in 
association with fatty acid 
induced insulin resistance 
Negative regulation of insulin 
signalling; potential serine-threonine 
phosphorylation of IRS proteins 
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2.2 Protein tyrosine phosphatase 1B, PTP1B 
Protein phosphorylation is reversible and controlled by the protein kinase (phosphorylate) 
and phosphatase (dephosphorylate), respectively, where these enzyme having opposing 
action mechanism. The phosphorylation of the tyrosine residues is essential to many signal 
transduction pathways triggered by hormones, mitogens and oncogenes that lead to 
processes such as cell growth, proliferation and differentiate (Fantl et al., 1993; Johnson et 
al., 2002). The role of protein tyrosine kinase (PTKs) are well documented since the 1980s 
and the role of protein tyrosine phosphatase (PTPs) was widely researched in 1990s 
(Charbonneau & Tonks, 1992; N. K. Tonks, 1993; Walton & Dixon, 1993).  
 
PTPs family is large where there are more than 40 members recorded by 1994 
(Barford et al., 1994) and the number had doubled to more than 100 in 2017. All the 
members of PTPs family are highly conserved at a 11 residues motif 
(I/V)HCXAGXXR(S/T)G where cysteine and arginine residues (Figure 2.4) act as the 
catalytic site of the enzyme. It is worth to mention that PTPs sequence shared no similarity to 
serine or threonine, acid and alkaline phosphatase (Charbonneau & Tonks, 1992). The 
diversity of the structure within the PTPs family is mainly occurs at non-catalytic sequences 
attached to theNH2- or COOH- termini of the catalytic domain.  
 
 PTP1B is the first PTP being isolated in homogeneous form and served as a model to 
illustrate several of the properties of PTPs. It was purified from human placenta as a 321 
amino acids protein (Charbonneau et al., 1989; N K Tonks et al., 1988). The cDNA 
indicated PTP1B is a 435 amino acids protein but the catalytic conserved motif occurred at 
residues 30 to 278. The COOH- terminal 35 residues of PTP1B targetted to the cytoplasmic 
face of the endoplasmic reticulum whereas preceding 122 residues are predominantly 
hydrophilic and contain sites for serine phosphorylation.  Overexpression of PTP1B retarded 
the action of oncogenic PTKs such as Src (Woodford-Thomas et al., 1992) and Neu (Brown-
Shimer et al., 1992). It is also linked to insulin signalling pathway (Kenner et al., 1993). 
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Figure 2.4 Important residues of PTP1B 
 
 
Figure 2.5 Topology diagram of PTP1B secondary structural elements. 
2-(oxalylamino)-benzoic acid 
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2.2.1 PTP1B Protein Crystal Structure in Protein Data Bank 
There are 124 PTP1B protein crystal structures of Homo sapiens and 2 structures from 
Oryctolagus cuniculus originated from more than 60 published journals (Table 2.8) are 
available in the Protein Data Bank (www.rcsb.org/pdb). The objectives of these published 
journals were varied from PTP1B inhibitor discoveries (Asante-Appiah et al., 2006; Douty et 
al., 2008; Groves et al., 1998; Liu et al., 2008; Zhao et al., 2004), chemical modification of 
PTP1B inhibitors oral drug design (Han et al., 2008; Iversen et al., 2000; Iversen et al., 
Scapin et al., 2003; Wan et al., 2007), insulin or insulin receptor related augmentation 
(Bleasdale et al., 2001; Salmeen et al., 2000), PTP1B protein structure understanding (Peters 
et al., 2000; Scapin et al., 2001; Wilson et al., 2007) and many more. These vigorous 
researches around the world displayed the importance and potential of PTP1B as a drug 
target.
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Table 2.8 PTP1B protein crystal structures in Protein Data Bank. 
PDB ID. 
(Resolution) PDB Title Published Journals References 
2NT7(2.1Å) 
2NTA(2.1Å) Crystal structure of PTP1B-inhibitor complex  Probing acid replacements of thiophene PTP1B inhibitors (Wan et al., 2007) 
1XBO(2.5Å) PTP1B comf1plexed with Isoxazole Carboxylic Acid Isoxazole carboxylic acids as protein tyrosine phosphatase 1B (PTP1B) inhibitors. (Zhao et al., 2004) 
3CWE(1.6Å) PTP1B in complex with a phosphonic acid inhibitor  
Discovery of [(3-bromo-7-cyano-2-
naphthyl)(difluoro)methyl]phosphonic acid, a potent and orally 
active small molecule PTP1B inhibitor 
(Han et al., 2008) 
1BZC(2.35Å) 
1BZH(2.1Å) 
1BZJ(2.25Å) 
Cyclic peptide inhibitor of human PTP1B Structural basis for inhibition of the protein tyrosine phosphatase 1B by phosphotyrosine peptide mimetics 
(Groves et al., 
1998) 
1LQF(2.5Å) Structure of PTP1b in Complex with a Peptidic Bisphosphonate Inhibitor  
The structure of PTP-1B in complex with a peptide inhibitor 
reveals an alternative binding mode for bisphosphonates 
(Asante-Appiah et 
al., 2002) 
1NWL(2.4Å) 
1NWE(3,1Å) 
Crystal structure of the PTP1B complexed with 
SP7343-SP7964, a ptyr mimetic 
Discovery of a New Phosphotyrosine Mimetic for PTP1B 
Using Breakaway Tethering 
(Erlanson et al., 
2003) 
3EAX(1.9Å) 
3EB1(2.4Å) 
Crystal structure PTP1B complex with small 
molecule compound LZP-6  
Targeting inactive enzyme conformation: aryl diketoacid 
derivatives as a new class of PTP1B inhibitors. (Liu et al., 2008) 
1L8G(2.5Å) 
Crystal structure of PTP1B complexed with 7-(1,1-
Dioxo-1H-benzo[d]isothiazol-3-yloxymethyl)-2-
(oxalyl-amino)-4,7-dihydro-5H-thieno[2,3-c]pyran-3-
carboxylic acid  
Steric hindrance as a basis for structure-based design of 
selective inhibitors of protein-tyrosine phosphatases 
(Iversen et al., 
2001) 
2VEU(2.4Å) 
2VEV(1.8Å) 
2VEW(2.0Å) 
2VEX(2.2Å) 
2VEY(2.2Å) 
Crystal Structure of Protein Tyrosine Phosphatase 1b 
In Complex with an Isothiazolidinone-Containing 
Inhibitor  
Isothiazolidinone Inhibitors of Ptp1B Containing Imidazoles 
and Imidazolines 
(Douty et al., 
2008) 
1G7G(2.2Å) 
1G7F(1.8Å) 
Human ptp1b catalytic domain complexes with 
pnu179326  
Small molecule peptidomimetics containing a novel 
phosphotyrosine bioisostere inhibit protein tyrosine 
phosphatase 1B and augment insulin action. 
(Bleasdale et al., 
2001) 
3EU0(2.7Å) Crystal structure of the S-nitrosylated Cys215 of PTP1B  
Cysteine S-Nitrosylation Protects Protein-tyrosine Phosphatase 
1B against Oxidation-induced Permanent Inactivation (Chen et al., 2008) 
 
 
21 
 
Table 2.8 PTP1B protein crystal structures in Protein Data Bank. (Cont.) 
PDB ID. 
(Resolution) PDB Title Published Journals References 
1Q6J(2.2Å) 
1Q6M (2.2Å) 
1Q6N(2.1Å) 
1Q6P(2.3Å) 
1Q6S(2.2Å) 
1Q6T(2.3Å) 
The structure of phosphotyrosine phosphatase 1b in 
complex with compound 2  
The Structural Basis for the Selectivity of Benzotriazole 
Inhibitors of Ptp1B (Scapin et al., 2003) 
1GFY(2.13Å) Residue 259 is a key determinant of substrate specificity 
of protein-tyrosine phosphatase 1b and alpha  
Residue 259 is a key determinant of substrate specificity 
of protein-tyrosine phosphatases 1B and alpha. (Peters et al., 2000) 
1C83(1.8Å) 
1C84(2.35Å) 
1C85(2.72Å) 
1ECV(1.95Å) 
Crystal structure of protein tyrosine phosphatase 1b 
complexed with 6-(oxalyl-amino)-1h-indole-5-carboxylic 
acid  
2-(oxalylamino)-benzoic acid is a general, competitive 
inhibitor of protein-tyrosine phosphatases 
(Andersen et al., 
2000). 
1C86(2.3Å) 
1C87(2.1Å) 
1C88(1.8Å) 
Crystal structure of protein tyrosine phosphatase 1b 
(r47v,d48n) complexed with 2-(oxalyl-amino-4,7-
dihydro-5h-thieno[2,3-c]pyran-3-carboxylic acid  
Structure-based design of a low molecular weight, 
nonphosphorus, nonpeptide, and highly selective 
inhibitor of protein-tyrosine phosphatase 1B. 
(Iversen et al., 
2000) 
2QBP(2.5Å) 
2QBQ(2.1Å) 
2QBR(2.3Å) 
2QBS(2.1Å) 
Crystal structure of ptp1b-inhibitor complex 
Structure-based optimization of protein tyrosine 
phosphatase 1B inhibitors: from the active site to the 
second phosphotyrosine binding site. 
(Wilson et al., 
2007) 
1EEN(1.9Å), 
1EEO(1.8Å) 
Crystal structure of protein tyrosine phosphatase 1b 
complexed with acetyl-d-a-d-bpa-ptyr-l-i-p-q-q-g  
 
Structural basis of plasticity in protein tyrosine 
phosphatase 1B substrate recognition. 
(M. Sarmiento et 
al., 2000) 
1PXH(2.15Å) Crystal structure of protein tyrosine phosphatase 1B with potent and selective bidentate inhibitor compound 2  
Crystal structure of PTP1B complexed with a potent and 
selective bidentate inhibitor. (Sun et al., 2003) 
2H4G(2.5Å) 
2H4K(2.3Å) 
2HB1(2.0Å) 
Crystal structure of PTP1B with monocyclic thiophene 
inhibitor  
Monocyclic thiophenes as protein tyrosine phosphatase 
1B inhibitors: Capturing interactions with Asp48. (Wan et al., 2006) 
1OEO(2.15Å) 
1OEM(1.8Å) Ptp1b with the catalytic cysteine oxidized to sulfonic acid  
Redox Regulation of Protein Tyrosine Phosphatase 
Involves a Sulfenyl-Amide Intermediate 
(Salmeen et al., 
2003) 
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Table 2.8 PTP1B protein crystal structures in Protein Data Bank. (Cont.) 
PDB ID. 
(Resolution) PDB Title Published Journals References 
2AZR(2.0Å) 
2B07(2.95Å) 
Crystal structure of PTP1B with Bicyclic Thiophene 
inhibitor  
Bicyclic and tricyclic thiophenes as protein tyrosine 
phosphatase 1B inhibitors. 
(Moretto et al., 
2006) 
3D9C(2.3Å) Crystal Structure PTP1B complex with aryl Seleninic acid  
 
Seleninate in place of phosphate: irreversible inhibition of 
protein tyrosine phosphatases. 
(Abdo et al., 
2008) 
2F6F(2.0Å) The structure of the S295F mutant of human PTP1B  Residues distant from the active site influence protein-tyrosine phosphatase 1B inhibitor binding. 
(Montalibet et al., 
2006) 
1PTY(1.85Å) 
1AAX(1.9Å) 
Crystal structure of protein tyrosine phosphatase 1b 
complexed with two phosphotyrosine molecules  
Identification of a second aryl phosphate-binding site in 
protein-tyrosine phosphatase 1B: a paradigm for inhibitor 
design. 
(Puius et al., 
1997) 
2F6T(1.7Å) 
2F6V(1.7Å) 
2F6W(2.2Å) 
2F6Y(2.15Å) 
2F6Z(1.7Å) 
2F70(2.12Å) 
2F71(1.55Å) 
Protein tyrosine phosphatase 1B with sulfamic acid 
inhibitors  
1,2,3,4-Tetrahydroisoquinolinyl sulfamic acids as 
phosphatase PTP1B inhibitors 
(Klopfenstein et 
al., 2006) 
1G1G(2.2Å) 
1G1H(2.4Å) 
1G1F(2.0Å) 
Crystal structure of protein tyrosine phosphatase 1b 
complexed with a mono-phosphorylated peptide 
(etdy(ptr)rkggkgll) from the insulin receptor kinase  
Molecular basis for the dephosphorylation of the 
activation segment of the insulin receptor by protein 
tyrosine phosphatase 1B. 
(Salmeen et al., 
2000) 
1Q1M(2.6Å) A Highly Efficient Approach to a Selective and Cell Active PTP1B inhibitors  
Fragment screening and assembly: a highly efficient 
approach to a selective and cell active protein tyrosine 
phosphatase 1B inhibitor. 
(Liu, Xin, Pei, et 
al., 2003) 
1JF7(2.2Å) Human ptp1b catalytic domain complexed with pnu177836  
Synthesis and biological activity of a novel class of small 
molecular weight peptidomimetic competitive inhibitors 
of protein tyrosine phosphatase 1B. 
(Larsen et al., 
2002) 
1ONY(2.15Å) 
1ONZ(2.4Å) 
 
Oxalyl-Aryl-Amino Benzoic Acid inhibitors of PTP1B, 
compound 17  
Discovery and Structure-Activity Relationship of 
Oxalylarylaminobenzoic Acids as Inhibitors of Protein 
Tyrosine Phosphatase 1B 
(Liu, 
Szczepankiewicz, 
et al., 2003) 
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Table 2.8 PTP1B protein crystal structures in Protein Data Bank. (Cont.) 
PDB ID. 
(Resolution) PDB Title Published Journals References 
2B4S(2.3Å) 
Crystal structure of a complex between PTP1B and the 
insulin receptor tyrosine kinase  
 
Crystal Structure of a Complex between Protein Tyrosine 
Phosphatase 1B and the Insulin Receptor Tyrosine Kinase. (Li et al., 2005) 
1I57(2.1Å) Crystal structure of apo human ptp1b (c215s) mutant  
 
The structure of apo protein-tyrosine phosphatase 1B 
C215S mutant: more than just an S --> O change. 
(Scapin et al., 
2001) 
1PH0(2.2Å) 
Non-carboxylic Acid-Containing Inhibitor of PTP1B 
Targeting the Second Phosphotyrosine Site  
 
Selective Protein Tyrosine Phosphatase 1B Inhibitors: 
Targeting the Second Phosphotyrosine Binding Site with 
Non-Carboxylic Acid-Containing Ligands. 
(Liu, Xin, Liang, 
et al., 2003) 
1WAX(2.2Å) 
Protein tyrosine phosphatase 1b with active site 
inhibitor  
 
Fragment-based lead discovery using x-ray crystallography (Hartshorn et al., 2005) 
2FJN(2.2Å) 
2FJM(2.1Å) 
The structure of phosphotyrosine phosphatase 1B in 
complex with compound 2  
Conformation-assisted inhibition of protein-tyrosine 
phosphatase-1B elicits inhibitor selectivity over T-cell 
protein-tyrosine phosphatase. 
(Asante-Appiah et 
al., 2006) 
2SHP(2.0Å) Tyrosine phosphatase shp-2  Crystal structure of the tyrosine phosphatase SHP-2. (Hof et al., 1998) 
1A5Y(2.5Å) Protein tyrosine phosphatase 1b cysteinyl-phosphate intermediate 
Visualization of the cysteinyl-phosphate intermediate of a 
protein-tyrosine phosphatase by x-ray crystallography. 
(Pannifer et al., 
1998) 
2PA5(1.6Å) Crystal structure of human protein tyrosine phosphatase PTPN9 
Large-scale structural analysis of the classical human 
protein tyrosine phosphatome. (Barr et al., 2009) 
1NZ7(2.4Å) 
Potent, selective inhibitors of PTP1B using a second 
phosphotyrosine binding site, complexed with 
compound 19 
Potent, selective inhibitors of protein tyrosine phosphatase 
1B. 
 
(Xin et al., 2003) 
1NL9(2.4Å) 
1NNY(2.4Å) 
1NO6(2.4Å) 
Potent, Selective Protein Tyrosine Phosphatase 1B 
Inhibitor Compound 12 Using a Linked-Fragment 
Strategy 
Discovery of a potent, selective protein tyrosine 
phosphatase 1B inhibitor using a linked-fragment strategy. 
 
(Szczepankiewicz 
et al., 2003) 
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2.2.2 PTP1B in diabetes and obesity 
Sedentary lifestyle and unbalanced diet with high fat intake have created a large overweight 
and obese population in the developing and developed countries. More than 30% of the adult 
population in the United State of America are considered obese. Obesity is defined as a 
medical state where the body weight (especially adipose tissue) reached a certain level where 
caused advert health problem to the person. The most popular among all measures is the 
waist/hip circumference ratio (WHR) and Body Mass Index (BMI) (Kopelman et al., 2009). 
In the case of BMI, according to WHO, any reading between BMI 25 to 30 is considered as 
overweight while readings above BMI of 30 will be categorised as obese. Since the ground 
breaking work of Vague in the year 1947 (Vague, 1956, 1996), it is slowly but widely 
accepted that different body morphology or types of fat distribution are independently 
related to the health risk associated with obesity. Vague was also the first to observe a 
constellation of the risk factor for T2DM, dyslipidemia and atherosclerosis in obese patient 
(Farooq et al., 2015).  
 
T2DM is strongly associated with obesity and insulin resistance acts as a common 
link between them. Another common factor between T2DM and obesity is the presence of 
PTP1B enzyme within the insulin and leptin signalling pathways which regulated blood 
glucose level and fatty acid homeostasis respectively. PTP1B acts as a negative regulator in 
both insulin (Figure 2.6) and leptin (Figure 2.7) signalling pathways. The inhibition of 
PTP1B might enhance the action of insulin and in turn advantageous to T2DM treatment 
(Zhang & Lee, 2003) as it avoids one of the most common side effect in T2DM treatment, 
that is the weight gain.  
 
 
 
 
 
